Stockscreener 앱 받기
2.6272
0.48%
-0.0128
시간 외 거래:
2.63
0.0028
+0.11%
전일 마감가:
$2.64
열려 있는:
$2.69
하루 거래량:
9,949
Relative Volume:
0.49
시가총액:
$4.25M
수익:
$8.62M
순이익/손실:
$-6.15M
주가수익비율:
-0.2382
EPS:
-11.03
순현금흐름:
$-5.32M
1주 성능:
-4.57%
1개월 성능:
-31.23%
6개월 성능:
-45.94%
1년 성능:
-56.34%
1일 변동 폭
$2.549
$2.69
1주일 범위
$2.46
$2.837
52주 변동 폭
$1.94
$12.32
Evoke Pharma Inc Stock (EVOK) Company Profile
명칭
Evoke Pharma Inc
전화
858-345-1494
주소
420 STEVENS AVENUE, SOLANA BEACH, CA
EVOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
2.6272 | 4.25M | 8.62M | -6.15M | -5.32M | -11.03 |
|
RGC
Regencell Bioscience Holdings Ltd
|
17.40 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
156.17 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.38 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.76 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2019-03-05 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-08 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-10-19 | 재개 | FBR & Co. | Buy |
| 2017-03-16 | 재확인 | Rodman & Renshaw | Buy |
| 2017-01-30 | 업그레이드 | Laidlaw | Neutral → Buy |
| 2017-01-05 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2016-12-23 | 재확인 | Rodman & Renshaw | Neutral |
| 2016-07-19 | 재확인 | FBR Capital | Outperform |
| 2016-07-19 | 다운그레이드 | Noble Financial | Buy → Hold |
| 2016-07-18 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2016-03-16 | 개시 | Northland Capital | Outperform |
| 2016-03-14 | 재확인 | Ascendiant Capital Markets | Buy |
| 2016-02-17 | 재개 | FBR Capital | Outperform |
| 2014-12-03 | 재확인 | MLV & Co | Buy |
| 2014-11-07 | 개시 | MLV & Co | Buy |
| 2014-04-22 | 개시 | Laidlaw | Buy |
| 2013-11-19 | 개시 | Aegis Capital | Buy |
모두보기
Evoke Pharma Inc 주식(EVOK)의 최신 뉴스
Evoke Pharma (NASDAQ:EVOK) Stock Price Crosses Below Two Hundred Day Moving Average – What’s Next? - Defense World
Spine Injury Solutions (OTCMKTS:SPIN) Stock Price Crosses Below 200-Day Moving Average – Should You Sell? - Defense World
Breakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK) - Yahoo Finance
Gastroparesis Treatment Market Booming Worldwide with - openPR.com
Diabetic Gastroparesis Pipeline 2025: Key Developments, - openPR.com
Geriatric Medicines Market Expands Globally with Aging - openPR.com
Diabetic Gastroparesis Treatment Market Size, Trends & - openPR.com
Global Geriatric Medicines Market Generated Opportunities, - openPR.com
Diabetic Gastroparesis Treatment Market in 2025-2032 Detailed - openPR.com
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Barclays PLC Makes New $122,000 Investment in Innovator Equity Defined Protection ETF – 2 Yr to July 2026 (BATS:AJUL) - Defense World
Raymond James Financial Inc. Takes Position in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
Evoke Pharma Reports Strong Q1 2025 Sales Growth - TipRanks
Evoke Pharma Reports First Quarter 2025 Financial Results and Pr - GuruFocus
Evoke Pharma, Inc. Q1 Loss Decreases, But Misses Estimates - Nasdaq
Evoke Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Evoke Pharma Q1 Operating Expenses USD 4.4 Million - marketscreener.com
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Evoke Pharma Reports 77% Increase in Q1 2025 Net Product Sales, Driven by GIMOTI Adoption and Provider Engagement - Nasdaq
Evoke Pharma (EVOK) to Release Earnings on Tuesday - Defense World
Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com - Defense World
StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Evoke Pharma (EVOK) to Present Key Metoclopramide Study at DDW 2025 | EVOK Stock News - GuruFocus
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia In - GuruFocus
Evoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025 - Nasdaq
Hudbay Signs Exploration Agreement with the Mosakahiken Cree Nation for the Talbot Deposit in Manitoba - The Manila Times
Evoke Pharma to Present New Data Comparing Tardive - GlobeNewswire
Groundbreaking Safety Analysis: How 100M+ Patient Study Could Reshape Metoclopramide Treatment Guidelines - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Functional Dyspepsia Drug Industry Report 2025-2034: Market Dynamics, Trends, and Forecasts - WhaTech
Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update - Defense World
FY2025 Earnings Estimate for TSE:MNO Issued By Cormark - Defense World
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - Yahoo Finance
Top Market Trend Impacting Digestive and Intestinal Remedies Development in the Coming Years:Technological ... - WhaTech
Evoke Pharma stock hits 52-week low at $2.01 amid downturn By Investing.com - Investing.com South Africa
Evoke Pharma stock hits 52-week low at $2.01 amid downturn - Investing.com India
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2024 Earnings Call Transcript - MSN
StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
US Reciprocal Tariffs Evoke Mixed Response From India Inc - Free Press Journal
Is The Market Punishing Lynch Group Holdings Limited (ASX:LGL) For Its Mixed Fundamentals? - AInvest
Gastroparesis Market Growth to Accelerate in Forecast Period - openPR.com
Evoke Pharma stock hits 52-week low at $2.43 amid challenges By Investing.com - Investing.com South Africa
Evoke Pharma stock hits 52-week low at $2.43 amid challenges - Investing.com India
Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Declines By 32.7% - Defense World
Tenaz Energy Corp. (OTCMKTS:ATUUF) Short Interest Update - Defense World
Evoke Pharma Inc (EVOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.07%
0.06%
자본화:
|
볼륨(24시간):